BACKGROUND
5-6 million people suffer from severe TBI (Traumatic Brain Injury) per year with approximately 110 000 deaths in the US and Europe. Severely brain-injured patients with refractory fever, is a vulnerable patient group with poor prognosis. TEQCool’s main focus is severe TBI, where temperature control can both reduce fever and the intracranial pressure, to improve functional outcome, reduce mortality and length-of-hospital stay. This patient group is treated at Neuro-ICUs with cooling treatments poorly fitted to their needs.
Preserve patients’ brain function with targeted brain temperature control. This we aim to
reach in strategic phases:
• develop and launch brain normothermia therapy for traumatic brain injury (TBI)
patients
• develop the therapy to fit patients that do not have an intracranial temperature
probe
• establish brain normothermia as gold standard across indications where
temperature control is established